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Because of the serological cross-reactivity among the ﬂaviviruses, molecular detection methods, such as
reverse-transcription polymerase chain reaction (RT-PCR), play an important role in the recent Zika
outbreak. However, due to the limited sensitivity, the detection window of RT-PCR for Zika viremia is
only about one week after symptom onset. By combining loop-mediated isothermal ampliﬁcation
(LAMP) and AC susceptometry, we demonstrate a rapid and homogeneous detection system for the Zika
virus oligonucleotide. Streptavidin-magnetic nanoparticles (streptavidin-MNPs) are premixed with LAMP
reagents including the analyte and biotinylated primers, and their hydrodynamic volumes are drama-
tically increased after a successful LAMP reaction. Analyzed by a portable AC susceptometer, the changes
of the hydrodynamic volume are probed as Brownian relaxation frequency shifts, which can be used to
quantify the Zika virus oligonucleotide. The proposed detection system can recognize 1 aM synthetic Zika
virus oligonucleotide in 20% serum with a total assay time of 27 min, which can hopefully widen the
detection window for Zika viremia and is therefore promising in worldwide Zika fever control.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Zika virus (ZIKV), the causative agent of the infectious disease
Zika fever, is a positive-sense RNA virus that belongs to the family
Flaviviridae, genus Flavivirus, which is related to dengue fever,
yellow fever, Japanese encephalitis and West Nile fever (Kuno
et al., 1998; Sikka et al., 2016). Until recently, Zika fever was con-
sidered mild and self-limited and therefore has received less at-
tention (Haug et al., 2016; Petersen et al., 2016). However, it has
recently been found that ZIKV infection could trigger Guillain-
Barré syndrome (Cao-Lormeau et al., 2016; Broutet et al., 2016);
and could also be associated with microcephaly fetal death (Fauci
and Morens, 2016; Brasil et al., 2016). ZIKV is mainly transmitted
by day-time active female Aedes aegypti and Aedes albopictus
mosquitoes (Sikka et al., 2016), but can also be transmitted sexu-
ally (Foy et al., 2011; Venturi et al., 2016; Oster et al., 2016; D’Or-
tenzio et al., 2016), from mother to the fetus (Calvet et al., 2016;
Melo et al., 2016; Schuler-Faccini et al., 2016), and potentially
through blood transfusion (Musso et al., 2014; Marano et al., 2016).
The recent outbreaks of ZIKV have drawn the world's attentionr B.V. This is an open access articl
e (M. Strömberg).towards this relatively unstudied virus, particularly for its asso-
ciation with the increased number of newborns presenting mi-
crocephaly reported in Brazil (Campos et al., 2015; Rodriguez-
Morales, 2015; Heukelbach et al., 2016).
The incubation period of Zika fever ranges from three to twelve
days after the bite of an infected mosquito, which is similar to
other infections caused by ﬂaviviruses (Goeijenbier et al., 2016;
Sikka et al., 2016), and the clinical signs persist for two to seven
days (Korzeniewski et al., 2016). Laboratory diagnostics of ZIKV are
based mainly on the analysis of serum, by using viral RNA and/or
antibody based detection methods (Haug et al., 2016; Al-Qahtani
et al., 2016). Due to serological cross-reactivity among ﬂaviviruses
in IgM-antibody based assays, diagnostics based on molecular
testing are considered more reliable (Haug et al., 2016). The cur-
rent prevalent molecular detection method is reverse-transcrip-
tion polymerase chain reaction (RT-PCR), which can detect 320
copies/μL (approximately 530 aM) ZIKV RNA in a total assay time
(excluding the time for RNA extraction) of about 90 min (Faye
et al., 2008; Faye et al., 2013; Musso et al., 2015). However, since
viremia decreases over time, RT-PCR based methods should be
performed during the ﬁrst seven days after symptom onset (Haug
et al., 2016; Buathong et al., 2015), when the ZIKV loads are re-
ported at the level of approximately 1 fM in body ﬂuid samples
(Lanciotti et al., 2008; Gourinat et al., 2015; Barzon et al., 2016);e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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serologic testing (Z four days after symptom onset, and IgM an-
tibodies persist from two weeks to several months) (Petersen
et al., 2016). Therefore, more sensitive and reliable molecular de-
tection methods are required to meet the challenge of ZIKV daily
diagnoses on blood donators, pregnant women and travelers from
areas with ongoing ZIKV transmission.
Among the reported isothermal molecular detection techni-
ques that have the potential to replace traditional PCR/RT-PCR,
loop-mediated isothermal ampliﬁcation (LAMP) has become an
excellent option due to its high ampliﬁcation efﬁciency, speciﬁcity,
low cost, time-saving protocol and the ability of amplifying non-
denatured DNA samples (Notomi et al., 2000; Tomita et al., 2008).
In our previous work (Tian et al., 2016b), we reported a LAMP
based optomagnetic biosensor, which could detect 10 aM synthetic
Newcastle disease virus DNA in 30 min. It has been demonstrated
that Bst 3.0 polymerase could amplify both RNA and DNA se-
quences under identical conditions, and the LAMP-optomagnetic
biosensor was veriﬁed by performing tests on clinical RNA samples
(vaccine and tissue specimens) (Tian et al., 2016b). The LAMP-
optomagnetic assay was performed in a three-step procedure in-
cluding ampliﬁcation, labeling and read-out. However, due to the
optical inﬂuence of the Mg2P2O7 precipitation, the LAMP-opto-
magnetic detection procedure required opening of the reaction
tube after the LAMP reaction, which greatly increased the risk of
carryover contamination (Tomita et al., 2008).
Here, we present a simple and homogeneous ZIKV detection
method that combines LAMP and a magnetic AC susceptibility
readout method based on the response of the magnetic nano-
particle (MNP) system, and the three step procedure is reduced to
a two-step procedure. Streptavidin-coated 100 nm magnetic na-
noparticles were mixed with LAMP reagents including biotinylated
inner primers prior to the reaction. During the LAMP reaction, the
hydrodynamic volume of the MNPs dramatically increased due to
binding between the streptavidin groups on the particles and the
biotinylated amplicons. Mg2P2O7, a by-product produced in a
successful LAMP reaction (Mori et al., 2001), was also involved in
the increase of the hydrodynamic volume of the MNPs. The in-
crease in hydrodynamic volume of the MNPs resulted in a Brow-
nian relaxation frequency shift to lower frequency which was
subsequently measured by a portable AC susceptometer (Astalan
et al., 2004). An increased target oligonucleotide concentration
resulted in a larger frequency shift to lower frequency. The LAMP-
AC susceptometer biosensor achieves a limit of detection (LOD) of
1 aM synthetic ZIKV oligonucleotide with a total assay time of
27 min. The same sensitivity was achieved when performing the
test in 20% serum samples. From these results we can hopefully
widen the detection window of ZIKV viremia and contribute to the
Zika fever control.2. Materials and methods
2.1. Reagents
Bst 3.0 polymerase, isothermal ampliﬁcation buffer II and
MgSO4 were purchased from New England Biolabs (Ipswich, UK).
dNTP mix was purchased from Thermo Fisher Scientiﬁc (Waltham,
USA). Fetal bovine serum, D-biotin and MQ water were purchased
from Sigma-Aldrich. Streptavidin modiﬁed 100 nm MNPs (multi-
core magnetic beads containing clusters of small single domain
particles, 10 mg/mL, 61012 particles/mL) were purchased from
Micromod (Rostock, Germany). For the serum sample detection,
10 nM synthetic ZIKV oligonucleotide was serial diluted with 20%
fetal bovine serum.2.2. Primer design
RNA-dependent-RNA-polymerase (NS5) sequences of 51 ZIKV
strains from the outbreak in Easter Island in 2014 (GenBank ac-
cession number: KM078929-KM078979) (Tognarelli et al., 2016)
were compared and a 230 bp highly conserved region (Table S1)
was chosen as the target gene for primer design. LAMP primers
(inner primer pair FIP/BIP, outer primer pair F3/B3 and loop primer
pair LF/LB) were designed using Primer Explorer version 4 (https://
primerexplorer.jp/e/), and the sequences are shown in Table S1.
The inner primer FIP was labeled with a biotin group at the 5′-end.
The target sequence and six primers were synthesized by In-
tegrated DNA Technologies (Coralville, USA).
2.3. LAMP reaction
A 100 μL reaction mixture contained 200 μg/mL MNPs (strep-
tavidin-coated MNPs or biotin-blocked MNPs), 1.6 μM inner pri-
mers, 0.2 μM outer primers, 0.4 μM loop primers, 1 isothermal
ampliﬁcation buffer II (containing 2 mM MgSO4), 6 mM MgSO4
(8 mM in total), 32 U Bst 3.0 polymerase, 1.4 mM dNTPs and 40 μL
of analyte solution (synthetic ZIKV oligonucleotide). The mixture
was incubated at 69 °C (metal bath) for 12 min
2.4. AC susceptometry measurement
After incubation, the reaction tube was mounted in a portable
commercial AC susceptometer, DynoMag
s
(Acreo Swedish ICT AB,
Göteborg, Sweden), to measure the frequency-dependent AC sus-
ceptibility. Sixteen data points were measured in the frequency
range of 4–100 Hz, and the readout time was 15 min. The fre-
quency-dependent out-of-phase component of the susceptibility,
χ″, was recorded. The position of the χ″ peak in frequency is de-
ﬁned as the Brownian relaxation frequency fB, which is given by
πη= ( )f k T V/ 6B B h , where k TB is the thermal energy, η is the dynamic
viscosity and Vh is the hydrodynamic volume of the relaxing entity.
2.5. Optimization of LAMP reaction
Agarose gel electrophoresis analysis was employed to evaluate
the inﬂuence of different reaction temperatures (61, 63, 65, 67, 69
and 71 °C) and different inner primer concentrations (0.4, 0.8 and
1.6 μM). Synthetic ZIKV oligonucleotide at a concentration of 1 pM
was used as analyte, and the Mg2P2O7 precipitations were re-
moved by centrifugation after 12 min ampliﬁcation. To ﬁnd an
optimum biotinylated inner primer to streptavidin-MNP ratio that
could balance the reaction efﬁciency and the blocking effect
caused by the excess of biotinylated primers, the inner primer
concentration vs. streptavidin-MNP concentration was evaluated
in the AC susceptometer by amplifying 1 fM synthetic ZIKV
oligonucleotide.
2.6. Scanning electron microscopy measurement
After the LAMP reaction, the MNPs (streptavidin-coated MNPs
or biotin-blocked MNPs) suspended in the reaction mixture were
separated by a magnetic stand, washed twice by 50 μL MQ water
and resuspended in 25 μL MQ water. A 100 μL control reaction
mixture (positive LAMP reaction without MNPs) was centrifuged,
washed twice with 50 μL MQ water and resuspended in 25 μL MQ
water to collect the Mg2P2O7 precipitation. The morphology and
nanostructure of the three samples (volume-ampliﬁed streptavi-
din-coated MNP aggregates, volume-ampliﬁed biotin-blocked
MNP aggregates and Mg2P2O7 precipitation) were characterized by
scanning electron microscopy (SEM, Zeiss-1530) using an in-lens
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at 3 kV electron beam accelerating voltage.3. Results and discussion
3.1. AC susceptometry detection and setup
An illustration of the LAMP based susceptometry biosassay is
presented in Fig. 1. Synthetic ZIKV oligonucleotides are mixed with
streptavidin-MNPs and other LAMP reagents including biotiny-
lated inner primers. Due to the binding of amplicons (and/or
Mg2P2O7) during the LAMP reaction, the hydrodynamic volume of
MNPs increases, which results in a shift in fB to lower frequency.
3.2. Optimization of LAMP reaction
Agarose gel electrophoresis analysis showed that the optimum
reaction temperature was 69 °C (Fig. S1A). At this temperature the
LAMP reaction produced a maximum amount of amplicons and
therefore this temperature was employed in the following tests.
Although Fig. S1B shows that the reaction efﬁciency can be im-
proved by increasing the concentration of inner primers, it may be
anticipated that the higher amount of biotinylated inner primer
would lead to a smaller fB shift, since the polymerase would
preferentially amplify the free inner primers instead of primers
that are already bound to MNPs (according to the supplier,
200 μg/mL streptavidin-MNPs can be saturated with approxi-
mately 0.02 μM biotin groups). Therefore, the shift in fB was
evaluated with respect to the inner primer concentration vs.
streptavidin-MNP concentration. As shown in Fig. S2, detection of
1 fM synthetic ZIKV oligonucleotides gave the largest fB shift with
1.6 μM inner primers and 200 μg/mL MNPs.
Considering that the biotin-streptavidin reaction is much faster
than the LAMP reaction, the streptavidin groups on the surface of
MNPs can be saturated by biotinylated primers before the primers
being ampliﬁed. Moreover, polymerases that bind to the surface of
MNPs contribute more to the MNP volume ampliﬁcation. There-
fore, a higher MNP concentration results in a lower amount of
polymerases on each MNP, and consequently in less amplicons on
each MNP (Fig. S2). The ampliﬁcation time was also optimized and
this was done by turbidity-based naked-eye detection (data not
shown). Due to the high ampliﬁcation efﬁciency and the end-point
detection format, signals of positive samples reach the saturation
level easily and are then not useful for quantiﬁcation. Therefore, a
longer reaction time results in a narrower dynamic detection
range. An ampliﬁcation time of 12 min was chosen to achieveFig. 1. Illustration of the LAMP based susceptometry assay. Two independent steps, in
cubation; target oligonucleotides are ampliﬁed and the product/byproduct interacts with
AC susceptometer and measured (for clarity, the excitation coil is shown with a sectionrapid attomolar target detection without narrowing the dynamic
detection range.
3.3. Quantitative synthetic ZIKV oligonucleotide detection
Serial dilutions of synthetic ZIKV oligonucleotides, ranging
from 1 pM to 100 zM, were ampliﬁed in presence of streptavidin-
MNPs and analyzed by the AC susceptometer; the spectra of χ″ are
shown in Fig. 2A, showing that fB shifts to lower values with in-
creasing analyte concentration. Three independent measurements
were performed for each analyte concentration. Since we focus
more on the peak position, the χ″ spectra were not normalized
with respect to χ′∞ (high-frequency value of the in-phase com-
ponent of the volume susceptibility) as done in previous work
(Zardán Gómez de la Torre et al., 2011). The typical spectra of the
three independent measurements are shown in this work, and fB
are extracted from each measurement for the following analysis.
Interestingly, the lowest fB observed in this work is 7.6 Hz
(Fig. 2A, 1 pM target sequence), which is much lower than ob-
served in previous work (approximately 36 Hz, 1 pM target se-
quence) (Tian et al., 2016b). The frequency peak obtained by the
optomagnetic setup is not exactly equal but very close to the fB
(Donolato et al., 2015; Tian et al., 2016a). The difference between
the protocol used in this work and the one used in previous work
is that in the previous work the biotinylated amplicons were in-
cubated with MNPs after the LAMP reaction. Therefore, we hy-
pothesize that the much larger shift in fB when using this new
protocol is explained not only by binding of MNPs to amplicons,
but also by the Mg2P2O7 precipitation that is formed during the
LAMP reaction and deposited onto the surface of the MNPs.
To verify this hypothesis, we ﬁrst investigated whether the
biotin-blocked streptavidin-MNPs could be volume-ampliﬁed by
incubating with already formed biotinylated amplicons or Mg2P2O7
precipitation. The biotinylated amplicons and the Mg2P2O7 pre-
cipitation were separated by centrifugation after the LAMP reac-
tion and incubated for 15 min at room temperature with biotin-
blocked MNPs, respectively. Fig. S3 shows that neither the bioti-
nylated amplicons nor the precipitated Mg2P2O7 could obviously
change fB of the biotin-blocked MNPs. This means that (1) the
streptavidin groups on the MNPs were completely blocked; (2) the
biotin-blocked MNPs have no interaction with the already formed
LAMP products and byproducts; and (3) the viscosity is not ob-
viously changed by the LAMP reaction.
Next we investigated whether biotin-blocked MNPs could be
volume-ampliﬁed during the LAMP reaction. The biotin-blocked
MNPs were mixed with LAMP reagents and the analyte, and re-
acted with serial dilutions of synthetic ZIKV samples; the ACcubation and measurement, are included in the illustration from left to right. In-
MNPs during the LAMP reaction. Measurement; the reaction tube is mounted in the
in the middle removed to reveal the pickup coil).
Fig. 2. Typical χ″ spectra for the indicated concentrations of synthetic ZIKV oligonucleotide. (A) Streptavidin-MNP based LAMP-AC susceptometry analysis. (B) Biotin-blocked
MNP based LAMP-AC susceptometry analysis.
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observed for ZIKV concentrations ≥ 100 aM, and the lowest ob-
served fB is about 20 Hz (1 pM analyte). This result clearly de-
monstrates that MNPs have an interaction with the Mg2P2O7
precipitation during its formation. This interaction was further
conﬁrmed by scanning electron microscopy (SEM).
The dose-response curves of fB vs. ZIKV oligonucleotide con-
centration are shown in Fig. 3 for triplicate measurements. The
cut-off value was calculated as the average signal of the blank
control samples minus three standard deviations, and the LOD was
deﬁned as the lowest ZIKV oligonucleotide concentration whose
value is below the cut-off. The LOD and dynamic detection range
of streptavidin-MNP based LAMP-AC susceptometry analysis were
1 aM and 1–103 aM, respectively. For the biotin-blocked MNP
based analysis, MNPs were volume-ampliﬁed only by the inter-
action with Mg2P2O7, and the sensitivity was reduced: an LOD ofFig. 3. Dose-response curves for synthetic ZIKV oligonucleotide detected by
streptavidin-MNP based (black circles) and biotin-blocked MNP based (red squares)
LAMP-AC susceptometry analysis. Error bars indicate one standard deviation based
on three independent measurements. Cut-off values are indicated by the horizontal
lines. (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.)32 aM was achieved. The average coefﬁcients of variation in the
dynamic detection range of streptavidin-MNP based and biotin-
blocked MNP based analysis were 9.75% and 8.95%, respectively.
3.4. Scanning electron microscopy study
By using SEM, we further investigated the hypothesis that MNP
can be volume-ampliﬁed by the deposition of Mg2P2O7 during the
LAMP. The MNPs were separated, washed and collected after the
LAMP reaction for SEM analysis (1 pM target analyte). Due to the
rigorous separation and washing procedure, the aggregates at-
tracted by the magnetic stand are considered to be MNPs with
strongly attached amplicons (for streptavidin-MNPs) and/or
Mg2P2O7 precipitation (for both streptavidin-MNPs and biotin-
blocked MNPs). Fig. 4 shows the morphology and nanostructures
of the collected volume-ampliﬁed MNP aggregates, as well as the
precipitated Mg2P2O7 that were collected from the control LAMP
reaction without MNPs. Compared to the regular nanostructures of
the Mg2P2O7 precipitation (Fig. 4C), magnetic aggregates based on
volume-ampliﬁed streptavidin-MNPs (Fig. 4A) and volume-am-
pliﬁed biotin-blocked MNP (Fig. 4B) contain a dense mass of ir-
regular Mg2P2O7 nanostructures. The existence of these irregular
Mg2P2O7 nanostructures or Mg2P2O7 fragments implies that MNPs
are involved in the formation of Mg2P2O7 nanostructures and have
a strong interaction with them. It is thus conﬁrmed that the
Mg2P2O7 precipitation occurs on the MNP surface during the LAMP
reaction, and results in an additional shift of fB. This phenomenon
also implies that other magnetic nanostructures can possibly serve
as labels of LAMP products without surface functionalization,
which can be further utilized to establish Mg2P2O7 deposition
based biosensors.
3.5. Spiked serum sample detection
Since blood analysis is a routine work in ZIKV diagnosis and
control, serum samples were tested by the proposed streptavidin-
MNP based LAMP-AC susceptometry assay. The matrix effects of
serum can slow down the ampliﬁcation and reduce the sensitivity
of the biosensor. After evaluation of several serum concentrations,
it was found that serum concentrations lower than 20% have no
obvious impact on the sensitivity of proposed system. Therefore,
synthetic ZIKV oligonucleotide samples were spiked into 20%
serum to simulate ﬁve times diluted pure serum samples, and
Fig. 4. Scanning electron microscopy images of volume-ampliﬁed streptavidin-MNP aggregates (A), volume-ampliﬁed biotin-blocked MNP aggregates (B) and precipitated
Mg2P2O7 nanostructures (C).
Fig. 5. 20% serum sample measurements. (A) Typical χ″ spectra for the indicated concentrations of synthetic ZIKV oligonucleotide. (B) Dose-response curve of streptavidin-
MNP based LAMP-AC susceptometry analysis. Error bars indicate one standard deviation based on three independent measurements. The cut-off value is indicated by the
horizontal line.
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system. The spectra and dose-response curve of 20% serum de-
tection are shown in Fig. 5. While the LOD (1 aM synthetic ZIKV
oligonucleotide) is preserved for the 20% serum samples, the dy-
namic detection range (approximately four orders of magnitude,
from 1 aM to 104 aM) is larger than for samples without serum
(approximately three orders of magnitude, Fig. 3). We attribute the
extended dynamic detection range to the matrix effects of the
serum, which can slow down the reaction but not inﬂuence the
equilibrium (the lowest fB is 7.9 Hz, nearly the same as for the
sample without serum). The average coefﬁcient of variation in the
dynamic detection range was 7.73% for 20% serum detection. The
result shows that detection on 20% serum samples can achieve an
LOD of 1 aM with a total assay time of 27 min (12 min LAMP and
15 min readout), which is two orders of magnitude more sensitive
and faster than the reported RT-PCR based ZIKV detection.3.6. Speciﬁcity evaluation
The speciﬁcity (selectivity) of the proposed streptavidin-MNP
based LAMP-AC susceptometry assay was investigated by con-
sidering four types of synthetic NS5 gene from relevant viruses
(Dengue virus, GenBank accession number: EF595819; Yellow fe-
ver virus, GenBank accession number: AY541441; Japanese en-
cephalitis virus, GenBank accession number: FJ515937; and West
Nile virus, GenBank accession number: AY187015) as negative
controls (synthesized by Integrated DNA Technologies). The syn-
thetic oligonucleotides were spiked into 20% serum at a con-
centration of 1 pM. Results presented in Fig. S4 show that the
responses from the negative controls are similar to the blank
control, indicating a high speciﬁcity of the proposed method.
4. Conclusion
This work presents a ﬁrst report of a LAMP-AC susceptometry
assay for rapid and highly sensitive quantitative ZIKV detection.
B. Tian et al. / Biosensors and Bioelectronics 86 (2016) 420–425 425The proposed detection system recognizes 1 aM synthetic ZIKV
oligonucleotide in 27 min. The assay has a dynamic detection
range of 1 aM-10 fM targets in 20% serum sample. Although we
only detected synthetic Zika virus DNA, we have demonstrated in a
previous paper that the enzyme (Bst 3.0 polymerase) could am-
plify both RNA and DNA sequences under identical conditions, and
performs well when detecting clinical RNA samples (vaccine and
tissue specimens) (Tian et al., 2016b). This method is approxi-
mately two orders of magnitude more sensitive and faster than the
reported RT-PCR based ZIKV serum detection (Faye et al., 2008;
Faye et al., 2013), and is thus a promising method for ZIKV diag-
nosis and control. In future work, a heating unit will be integrated
into the AC susceptometer in order to automate and simplify the
detection procedure.Acknowledgments
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